Kentucky Retirement Systems Insurance Trust Fund Sells 1,600 Shares of Edwards Lifesciences Co. (NYSE:EW)

Kentucky Retirement Systems Insurance Trust Fund decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.2% during the third quarter, Holdings Channel.com reports. The fund owned 17,836 shares of the medical research company’s stock after selling 1,600 shares during the quarter. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Edwards Lifesciences were worth $1,177,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in EW. Park Avenue Securities LLC grew its position in shares of Edwards Lifesciences by 0.5% during the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares in the last quarter. City State Bank raised its position in shares of Edwards Lifesciences by 16.5% during the second quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after buying an additional 130 shares during the last quarter. Stableford Capital II LLC lifted its holdings in shares of Edwards Lifesciences by 2.7% in the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after buying an additional 159 shares in the last quarter. Purus Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 5.2% during the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after acquiring an additional 160 shares during the last quarter. Finally, Busey Bank grew its stake in Edwards Lifesciences by 1.9% during the second quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 165 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 4.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,250 shares of company stock worth $2,744,438. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Up 2.4 %

Shares of NYSE:EW opened at $67.76 on Monday. The business’s 50 day moving average is $67.44 and its 200 day moving average is $76.12. The stock has a market cap of $39.96 billion, a P/E ratio of 9.78, a price-to-earnings-growth ratio of 3.81 and a beta of 1.12. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 EPS. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on EW shares. Royal Bank of Canada dropped their price objective on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, July 25th. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.